Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.

The development of molecules embedding two distinct pharmacophores acting as muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to reduce formulation issues and boost efficacy through cross-talk and allosteric interactions. Herein, we report the results of our drug discovery campaign aimed at improving the therapeutic index of a previous MABA series by exploiting the super soft-drug concept. The incorporation of a metabolic liability, stable at the site of administration but undergoing rapid systemic metabolism, to generate poorly active and quickly eliminated fragments was pursued. Our SAR studies yielded MABA 29, which demonstrated a balanced in vivo profile up to 24 h, high instability in plasma and the liver, as well as sustained exposure in the lung. In vitro safety and non-GLP toxicity studies supported the nomination of 29 (CHF-6366) as a clinical candidate, attesting to the successful development of a novel super-soft MABA compound.

[1]  Dave Singh.  Pharmacological treatment of stable chronic obstructive pulmonary disease , 2021, Respirology.

[2]  B. Riccardi,et al.  Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). , 2021, Bioorganic & medicinal chemistry letters.

[3]  M. Cazzola,et al.  Prospects for COPD treatment. , 2020, Current opinion in pharmacology.

[4]  H. Pettersson,et al.  Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel "Dual-Soft" PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis. , 2020, Journal of medicinal chemistry.

[5]  Dave Singh,et al.  Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator , 2020, Respiratory Research.

[6]  K. Dack,et al.  Topical 'dual-soft' glucocorticoid receptor agonist for dermatology. , 2020, Bioorganic & medicinal chemistry letters.

[7]  Dave Singh,et al.  Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When? , 2020, Clinics in chest medicine.

[8]  K. Read,et al.  Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1 , 2018, Bioorganic & medicinal chemistry letters.

[9]  D. Sejer Pedersen,et al.  Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. , 2017, Journal of medicinal chemistry.

[10]  M. Mammen,et al.  Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β , 2015, Journal of medicinal chemistry.

[11]  Edwin K. Silverman,et al.  Chronic obstructive pulmonary disease , 2012, Nature Reviews Disease Primers.

[12]  M. Cazzola,et al.  Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease , 2014, European Respiratory Journal.

[13]  P. Jennum,et al.  Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010 , 2014, BMJ Open.

[14]  Arthur Christopoulos,et al.  Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.

[15]  Mario Cazzola,et al.  Pharmacology and Therapeutics of Bronchodilators , 2012, Pharmacological Reviews.

[16]  L. Jones,et al.  Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease. , 2011, Future medicinal chemistry.

[17]  M. Mammen,et al.  THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent Manner , 2011, Molecular Pharmacology.

[18]  S. Sentellas,et al.  Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[ , 2009, Journal of medicinal chemistry.